Remote Intervention to Prevent Overdose

Conditions

• Accidental Overdose of Opiate

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Overdose prevention resources — OTHER
  Overdose prevention resources (e.g., naloxone) are resources used to prevent drug overdose.
• Overdose prevention education — BEHAVIORAL
  Developed in the R61 phase, the educational intervention will provide participants with knowledge about how prevent drug overdose.

Study Details

This Type 1 hybrid effectiveness-implementation randomized controlled trial, A Remote Intervention to Prevent Overdose among People who Use Stimulants and/or Opioids, aims to address the United States opioid crisis driven by fentanyl and other synthetic opioids by reducing overdose rates. It is supported by and included in the HEAL Initiative. This study would be the first national, fully remote trial to assess the impact of remote education on overdose outcomes, using a novel 2x2 design crossing remote education with remote access support. This research will inform scalability around remote education programs to address the nation's opioid overdose crisis.

Key Dates

First listed

Aug 19, 2025

Start date

Jan 31, 2027

Status verified

Jun 2026

Primary completion

Nov 30, 2027

Completion

Nov 30, 2027

Study Design

Enrollment

100 participants (estimated)

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

PREVENTION

Arms

• Experimental: Education plus access support
  This arm receives both overdose prevention education and access to overdose prevention resources.
• Experimental: Education only
  The Education only arm receives overdose prevention education.
• Experimental: Access support
  This arm receives access to overdose prevention resources.
• No Intervention: Referral
  The referral only arm receives a resource list for obtaining naloxone and other overdose prevention resources on their own.

Primary Outcome Measure

Overdose [ Time Frame: Baseline, 1 month, 3 months, 6 months ]

Central Contacts

• Emma S Kay, PhD, MSW
  205-996-5547
  [email protected]

Locations (2)

Find similar trials in Birmingham, AL